Approval Year
Name | Type | Language |
---|
Showing 1 to 5 of 8 entries
Related Record | Type | Details |
---|
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->INHIBITOR OF AGGREGATION |
A?pE is of interest as it has been shown to be one of the dominant forms of A? present in the hippocampi and cortices of patients with Alzheimer's disease. However, arguably of most importance is that A?pE is specifically only found within cerebral A? plaques.2 In-vitro analysis has revealed that A?pE3 shows an increased rate of aggregation up to 250 times that of full-length A?, irrespective of its C terminus.
|
||
|
TARGET->INHIBITOR OF AGGREGATION |
A?pE is of interest as it has been shown to be one of the dominant forms of A? present in the hippocampi and cortices of patients with Alzheimer's disease. However, arguably of most importance is that A?pE is specifically only found within cerebral A? plaques.2 In-vitro analysis has revealed that A?pE3 shows an increased rate of aggregation up to 250 times that of full-length A?, irrespective of its C terminus.
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
Showing 1 to 3 of 3 entries
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
ESTIMATED
C6452H9994N1708O2016S42 |
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
ESTIMATED
145000 Da (average) |
Showing 1 to 2 of 2 entries